BioCentury | Jan 12, 2021
Finance

Seeking to fill gap in the clinic, LSP raises €50M toward dementia-focused fund

European investment firm LSP has launched a new dementia-focused fund to fill what it believes is a gap in support for development-stage companies evaluating treatments for neurodegenerative diseases. The firm has named Philip Scheltens, who...
BioCentury | Oct 31, 2020
Regulation

Expanding access to COVID-19 vaccines

As lightning-quick vaccine development comes close to catching up with a runaway pandemic, FDA must quickly decide how it will respond to the first clear signs that a vaccine candidate may be effective.  ...
BioCentury | Oct 17, 2020
Product Development

Bourla, FDA leaders say two-month follow-up key to timing for COVID-19 vaccine authorization

An open letter from Pfizer’s Albert Bourla and a commentary from FDA’s heads of vaccine research and review respectively spell out how FDA’s guidance is shaping the timeline for what could be the first COVID-19...
BioCentury | Sep 17, 2020
Product Development

Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies

Arrowhead gains on AAT deficiency dataArrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained nearly $1.4 billion in market cap Wednesday after sharing interim data from four alpha-antitrypsin (AAT) deficiency patients treated with ARO-AAT in the Phase II AROAAT2002...
BioCentury | Jul 23, 2020
Emerging Company Profile

On track for 2021 launch, Seer unveils unbiased proteomics tech and latest $55M round

With a fresh $55 million and a new publication detailing its nanoparticle-based technology, Seer thinks it can bring the scale and speed of next-generation sequencing to proteomics next year. On Wednesday, Seer announced a series...
BioCentury | Jun 24, 2020
Product Development

Action needed to prevent manufacturing bottlenecks on COVID-19 therapies

Demand for COVID-19 therapies could far exceed supplies unless urgent steps are taken to prioritize and expand manufacturing capacity for the most promising therapeutic candidates, according to biopharma industry executives and public policy scholars. A...
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

Even if COVID-19 does disrupt operations or create a buyer’s market, Novartis will not veer from its business development strategy. The pharma was already expanding external innovation before the crisis, and has no intention of...
BioCentury | Mar 31, 2020
Finance

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

...designed to invest €15-€25 million per company. Disclosed investors in the new fund include Royal Philips...
BioCentury | Mar 26, 2020
Emerging Company Profile

ReCode: merging RNA therapies and organ-specific delivery for respiratory diseases

ReCode Therapeutics launched on Thursday with an OrbiMed- and Colt Ventures-led $80 million series A round to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology. The company was formed...
BioCentury | Feb 15, 2020
Product Development

WHO mapping out COVID-19 vaccines

Scientists from biopharma companies, universities and regulatory agencies met at the WHO Feb. 11-12 to draw a roadmap for the development of vaccines to protect against COVID-19 amid a rapidly shifting terrain. While knowledge about...
Items per page:
1 - 10 of 543
BioCentury | Jan 12, 2021
Finance

Seeking to fill gap in the clinic, LSP raises €50M toward dementia-focused fund

European investment firm LSP has launched a new dementia-focused fund to fill what it believes is a gap in support for development-stage companies evaluating treatments for neurodegenerative diseases. The firm has named Philip Scheltens, who...
BioCentury | Oct 31, 2020
Regulation

Expanding access to COVID-19 vaccines

As lightning-quick vaccine development comes close to catching up with a runaway pandemic, FDA must quickly decide how it will respond to the first clear signs that a vaccine candidate may be effective.  ...
BioCentury | Oct 17, 2020
Product Development

Bourla, FDA leaders say two-month follow-up key to timing for COVID-19 vaccine authorization

An open letter from Pfizer’s Albert Bourla and a commentary from FDA’s heads of vaccine research and review respectively spell out how FDA’s guidance is shaping the timeline for what could be the first COVID-19...
BioCentury | Sep 17, 2020
Product Development

Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies

Arrowhead gains on AAT deficiency dataArrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained nearly $1.4 billion in market cap Wednesday after sharing interim data from four alpha-antitrypsin (AAT) deficiency patients treated with ARO-AAT in the Phase II AROAAT2002...
BioCentury | Jul 23, 2020
Emerging Company Profile

On track for 2021 launch, Seer unveils unbiased proteomics tech and latest $55M round

With a fresh $55 million and a new publication detailing its nanoparticle-based technology, Seer thinks it can bring the scale and speed of next-generation sequencing to proteomics next year. On Wednesday, Seer announced a series...
BioCentury | Jun 24, 2020
Product Development

Action needed to prevent manufacturing bottlenecks on COVID-19 therapies

Demand for COVID-19 therapies could far exceed supplies unless urgent steps are taken to prioritize and expand manufacturing capacity for the most promising therapeutic candidates, according to biopharma industry executives and public policy scholars. A...
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

Even if COVID-19 does disrupt operations or create a buyer’s market, Novartis will not veer from its business development strategy. The pharma was already expanding external innovation before the crisis, and has no intention of...
BioCentury | Mar 31, 2020
Finance

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

...designed to invest €15-€25 million per company. Disclosed investors in the new fund include Royal Philips...
BioCentury | Mar 26, 2020
Emerging Company Profile

ReCode: merging RNA therapies and organ-specific delivery for respiratory diseases

ReCode Therapeutics launched on Thursday with an OrbiMed- and Colt Ventures-led $80 million series A round to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology. The company was formed...
BioCentury | Feb 15, 2020
Product Development

WHO mapping out COVID-19 vaccines

Scientists from biopharma companies, universities and regulatory agencies met at the WHO Feb. 11-12 to draw a roadmap for the development of vaccines to protect against COVID-19 amid a rapidly shifting terrain. While knowledge about...
Items per page:
1 - 10 of 543